Lofexidine Gets US FDA Panel Nod For Mitigating Opioid Withdrawal Symptoms

 
• By Sue Sutter

But Psychopharmacologic Drugs Advisory Committee says US WorldMeds' second proposed indication for facilitating completion of opioid discontinuation treatment is not supported by data from two short-term studies in an 'idealized' population.

FDA Advisory Committee Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers